Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Biological Pathways and In Vivo Anti-Tumor Activity Induced by Atiprimod in Multiple Myeloma (MM).

Paola Neri, MD, Pierfrancesco Tassone, MD, Masood Shammas, PhD, Hiroshi Yasui, MD, Ernestina Schipani, MD, Ramesh B. Batchu, PhD, Simona Blotta, MD, Rao Prabhala, PhD, Laurence Catley, MD, Makoto Hamasaki, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Gary S. Jacob, PhD, Donald Picker, PhD, Salvatore Venuta, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2006) 108 (11): 3455.

https://doi.org/10.1182/blood.V108.11.3455.3455

Published: 2006

Journal Articles

The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.

Klaus Podar, MD, PhD, Melissa Simoncini, BS, Yu-Tzu Tai, PhD, Martin Sattler, PhD, Kenji Ishitsuka, MD, PhD, Steven Le Gouill, MD, Makoto Hamasaki, MD, PhD, Renate Burger, PhD, Noopur Raje, MD, Teru C. Hideshima, MD, PhD, Dharminder Chauhan, JD, PhD, Kenneth Anderson, MD

Blood (2004) 104 (11): 3352.

https://doi.org/10.1182/blood.V104.11.3352.3352

Published: 2004

Journal Articles

In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Aldo Roccaro, MD, Hiroshi Yasui, MD, Makoto Hamasaki, MD, Norihiko Shiraishi, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Simon R. Green, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 3359.

https://doi.org/10.1182/blood.V104.11.3359.3359

Published: 2004

Journal Articles

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Teru Hideshima, MD, PhD, Klaus Podar, MD, PhD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Makoto Hamasaki, MD, PhD, Noopur Raje, MD, Hiromasa Hideshima, George Schreiner, MD, PhD, Aaron Nguyen, PhD, Tony Navas, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Linda S. Higgins, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 3348.

https://doi.org/10.1182/blood.V104.11.3348.3348

Published: 2004

Journal Articles

Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.

Teru Hideshima, MD, PhD, Pierfrancesco Tassone, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Constantine Mitsiades, MD, PhD, Noopur Raje, MD, Shaji Kumar, MD, Makoto Hamasaki, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, David Schenkein, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2351.

https://doi.org/10.1182/blood.V104.11.2351.2351

Published: 2004

Journal Articles

TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.

Toshiaki Hayashi, MD, PhD, Teru Hideshima, MD, PhD, Klaus Podar, MD, PhD, Paul Richardson, MD, Olivier Munoz, MD, Makoto Hamasaki, MD, PhD, Kenji Ishitsuka, MD, PhD, Hiroshi Yasui, MD, PhD, Alison Murphy, PhD, Glenn McEnroe, PhD, Sarvajit Chakravarty, PhD, Sundeep Dugar, PhD, Linda S. Higgins, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2355.

https://doi.org/10.1182/blood.V104.11.2355.2355

Published: 2004

Journal Articles

Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues.

Shaji Kumar, MD, Noopur Raje, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Aldo Roccaro, MD, Norihiko Shiraishi, MD, Makoto Hamasaki, MD, Hiroshi Yasui, MD, Nikhil C. Munshi, MD, William D. Figg, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2406.

https://doi.org/10.1182/blood.V104.11.2406.2406

Published: 2004

Journal Articles

Induction of Apoptosis by Didox Via Down-Regulation of Bcl-2 Family Proteins in Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Aldo Roccaro, MD, Hiroshi Yasui, MD, Makoto Hamasaki, MD, Norihiko Shiraisi, PhD, Nikhil C. Munshi, MD, Howard Elford, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 4842.

https://doi.org/10.1182/blood.V104.11.4842.4842

Published: 2004

NARROW

Biological Pathways and In Vivo Anti-Tumor Activity Induced by Atiprimod in Multiple Myeloma (MM).

The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.

In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM).

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.

TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.

Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues.

Induction of Apoptosis by Didox Via Down-Regulation of Bcl-2 Family Proteins in Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only